Oncology Central

High incidence of febrile neutropenia seen following adjuvant chemotherapy with docetaxel plus cyclophosphamide for early breast cancer


Lakhanpal et al. conducted a multicenter retrospective audit in seven Australian centers to determine the incidence of febrile neutropenia (FN) and neutropenia associated with the use of docetaxel plus cyclophosphamide (TC) in women with early breast cancer who did not receive primary prophylaxis with G-CSF or antibiotics [1]. Of the 300 evaluable female patients 73 (24.3%) developed FN with the incidence higher after cycle 1 of TC.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.